I still say the key near-term for CLDX is the 011 update next month at the SABCS. I am holding in full through that event. CLDX also just said at Lazard they intend to expand testing of 011 into other indications where they see high GPNMB. Hopefully this bodes well for the update in breast cancer at the SABCS but, as always, no guarantees.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.